Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


Association of Community Cancer Centers' 2013 Innovator Award Recipients Take Spotlight at National Oncology Conference

October 8th 2013

Ten cancer programs that have developed pioneering solutions to address the challenges of treating cancer patients have received the Association of Community Cancer Centers' 2013 Innovator Awards.

National Cancer Institute Awards Leukemia Reseachers at Siteman $26 Million

October 7th 2013

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

Free Head, Neck Cancer Screenings Have Positive Impact in Urban Areas

October 4th 2013

Offering free head and neck cancer screenings annually to the community not only has the possibility of early detection, but also the opportunity – particularly in an urban city – to increase a person's understanding of risk factors that cause cancer, according to a new study from Henry Ford Hospital in Detroit.

ACCC Institute Calls for Collaboration, Adaptation to Maximize Patient Care Delivery amid Consolidation

October 4th 2013

In response to the growing trend of hospital consolidation, including questions about cancer care decision-making, cost impacts, and delivery of care, the ACCC Institute for the Future of Oncology has released a new white paper that provides perspectives on how these alignments are affecting cancer care providers, cancer programs, and the patients they serve.

Dr. Carbone on Potential Biomarkers in Lung Cancer

October 3rd 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

Merrimack Pharmaceuticals Completes Enrollment of Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer

October 3rd 2013

Merrimack Pharmaceuticals, Inc. announced today that the last patient has been enrolled in the second cohort of a two-cohort randomized Phase 2 clinical trial of MM-121 in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer.

The State of Oncology Practice: A Discussion With Anupama Kurup Acheson, MD

October 2nd 2013

Increasing financial and administrative pressures-exacerbated by the federal sequester and continued rollout of the Affordable Care Act-have created instability and uncertainty for oncology practices nationwide.

Dr. Hudis on BOLERO-3 Trial Biomarker Observations

October 1st 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, comments on exploratory biomarker observations from the BOLERO-3 trial.

Merck Announces Global Initiative to Sharpen Commercial and R&D Focus

October 1st 2013

Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015, this includes a plan for new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions.

FDA Approves Neoadjuvant Pertuzumab Regimen

September 30th 2013

Pertuzumab in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer

Personalized Medicine in Colorectal Cancer

September 29th 2013

Novel Therapies in Development for mCRC

September 29th 2013

Second-Line and Salvage Treatment of mCRC

September 29th 2013

Antiangiogenic Therapy in Metastatic Colorectal Cancer

September 29th 2013

Maintenance Therapy in Metastatic Colorectal Cancer

September 29th 2013

Case Study: Borderline Resectable mCRC

September 29th 2013

Predictive Value of RAS Mutations in mCRC

September 29th 2013

FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC

September 29th 2013

EPOC Studies: Preoperative Treatments in CRC

September 29th 2013

PRIME Trial: RAS Mutations in Metastatic Colorectal Cancer

September 29th 2013